Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...

Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly promising ...

One patient on islatravir/lenacapavir did show a detectable viral load of more than 50 copies/mL at 24 weeks, but fell below that threshold at 30 weeks, according to Gilead and MSD, and two ...

namely ViiV Healthcare with cabotegravir and Merck & Co’s islatravir (MK-8591). The 36-patient CAPELLA trial tested lenacapavir in highly treatment-experienced HIV patients who had developed ...

But will doctors use it? In its push to gain approval for its long-acting answer lenacapavir, Gilead also has reported stellar results from two phase 3 trials including the PURPOSE 1 study ...

But in terms of HIV preventions, there is already another groundbreaking drug called lenacapavir. The anti-HIV compound is already in use, but getting the drug to those who need it most could ...

Moldovan voters appeared leery of a move to enshrine in their Constitution an “irreversible” commitment to abandon Russian influence and one day join the European Union. By Andrew Higgins ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The twice-yearly injectable lenacapavir from Gilead Sciences emerged as a significant innovation, showing promising results in preventing HIV acquisition. Lenacapavir’s potential to be a “game ...